Tuberculosis remains one of the most consequential infectious disease challenges of our era — not because it is newly discovered, but because the gap between what is achievable and what has been achieved is widening dangerously. A landmark GBD 2023 analysis quantifying TB's toll across 204 countries over three decades offers the most comprehensive pre-disruption baseline available, arriving precisely when global health funding cuts threaten to erase hard-won gains.
The analysis applied the Cause of Death Ensemble modeling framework alongside DisMod-MR 2.1 to simultaneously estimate incidence, prevalence, and mortality by age, sex, HIV status, and drug-resistance category across 1990–2023. Global TB mortality declined approximately 37% over the study period, a meaningful but insufficient trajectory. Multidrug-resistant TB (MDR-TB) emerged as the critical inflection point: its burden has not followed the same downward arc as drug-susceptible TB, and in several high-burden regions it represents a growing share of total TB deaths. Disability-adjusted life-years (DALYs) were decomposed to capture both premature mortality and years lived with disability. Modifiable risk factors — alcohol use, smoking, and elevated fasting plasma glucose — were quantified via comparative risk assessment, collectively accounting for a substantial fraction of attributable burden, underscoring that TB is not solely an infectious disease problem but a metabolic and behavioral one as well.
The WHO End TB Strategy targets — a 95% mortality reduction and 90% incidence reduction by 2035 relative to 2015 — appear increasingly out of reach for most regions at current rates of decline. This analysis is particularly valuable because it establishes a pre-disruption benchmark: recent reductions in development assistance for health mean future GBD cycles may document a reversal rather than continuation of progress. The HIV-TB co-epidemic remains disproportionately concentrated in sub-Saharan Africa, where integrated care delivery is still fragmented. The MDR-TB trajectory is arguably the most alarming signal here — it represents a convergence of diagnostic gaps, treatment adherence failures, and antimicrobial stewardship shortfalls that no single intervention can resolve. Epidemiologically, this is a confirmatory but critically timed study: not paradigm-shifting in mechanism, but essential for accountability and policy recalibration.